The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Douglas Hanahan, Ping-Chih Ho receive appointments at Ludwig Cancer Research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Douglas Hanahan

Ping-Chih Ho

Douglas Hanahan was named a Distinguished Scholar at the Lausanne Branch of the Ludwig Institute for Cancer Research. A pioneering molecular biologist and renowned cancer researcher, Hanahan has made several seminal discoveries in cancer biology and immunology over the course of his career.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere. 
By Claire Marie Porter and Paul Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account